Compare FRSX & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSX | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 1.7B |
| IPO Year | 2016 | 1996 |
| Metric | FRSX | VCEL |
|---|---|---|
| Price | $1.89 | $46.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | ★ 1.6M | 710.2K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $0.31 | $28.95 |
| 52 Week High | $3.00 | $47.06 |
| Indicator | FRSX | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 77.16 |
| Support Level | $1.24 | $32.47 |
| Resistance Level | $1.90 | N/A |
| Average True Range (ATR) | 0.16 | 1.72 |
| MACD | 0.04 | 0.63 |
| Stochastic Oscillator | 70.00 | 99.19 |
Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.